Track topics on Twitter Track topics that are important to you
Clinical response can be challenging to predict in some cancers, but new research has shown the ability to predict CR to sunitinib (Sutent) in patients with advanced renal cell carcinoma (RCC).
US-based Celldex Therapeutics has started an open-label, Phase I/II safety and tolerability trial evaluating the investigational combination of varlilumab and sunitinib (Sutent) in patients with metas...
Receptor tyrosine kinase (RTK) targeted therapy has been explored for glioblastoma treatment. However, it is unclear which RTK inhibitors are the most effective and there are no predictive biomarkers ...
Tyrosine kinase inhibitor sunitinib (used in GIST, advanced RCC and pancreatic neuroendocrine tumors) undergoes CYP3A4 metabolism and is an ABCB1B and ABCG2 efflux transporters substrate. We assessed ...
Vascular endothelial growth factor (VEGF) and mammalian target of rapamycin are well-known therapeutic targets for renal cell carcinoma (RCC). Sunitinib is an agent that targets VEGF receptors and is ...
The angiogenesis inhibitor sunitinib is a tyrosine kinase inhibitor that acts mainly on the VEGF and PDGF pathways. We have previously shown that sunitinib is sequestered in the lysosomes of exposed t...
The randomized phase III trial of sunitinib versus interferon Alfa provided level-A evidence for the use of sunitinib in advanced clear cell renal cell carcinoma (RCC). This systematic literature revi...